Amyotrophic Lateral Sclerosis (ALS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Amyotrophic Lateral Sclerosis (ALS) Market Outlook

Thelansis’s “Amyotrophic Lateral Sclerosis (ALS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Amyotrophic Lateral Sclerosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Amyotrophic Lateral Sclerosis (ALS) Overview

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a degenerative disorder of the nervous system that manifests as progressive muscle wasting and weakness. It is both debilitating and fatal, typically occurring later in life. The disease advances swiftly, with a median survival period of three to five years, and only 20% of patients survive five to ten years after symptom onset. Respiratory failure is the most common cause of death in ALS patients. Despite the generally grim prognosis, there is significant variability in survival rates. As many as 10% of individuals with ALS manage to live more than eight years following the emergence of initial symptoms. Genetic risk factors include gene mutations such as SOD1, TARDBP, FUS, C9orf72, TBK1, and NEK1. Most of these risk factors have been uncovered within the past decade. Currently, the U.S. Food and Drug Administration (FDA) has approved seven drugs for the treatment of ALS and its associated symptoms. These medications include Qalsody, RELYVRIO, Radicava, Rilutek, Tiglutik, Exservan, and Nuedexta.

• ALS prevalence in the United States ranges between 5.2 and 6.5 cases per 100,000 population, whereas incidence cases range between o.6 and 2.8 cases per 100,000 population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: